CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 27, 2018—Qiagen has introduced next-generation sequencing solutions for a range of hereditary diseases on its GeneReader NGS System. The customizable QIAact target enrichment panels enable the analysis of more than 13 hereditary disease groups, including inherited cancers, cystic fibrosis, inherited cardiovascular diseases, and universal carrier screening. The solutions integrate the company’s QCI analysis, which includes the Human Gene Mutation Database, a knowledge base containing comprehensive data on inherited disease mutations for genetic and genomic research.
“Genetic laboratories are eager to gain deeper insights into a range of hereditary diseases by using the power of NGS technology but have been held back by the lack of complete workflows and powerful bioinformatics solutions,” Peer M. Schatz, CEO of Qiagen, said in a press release. “We are pleased to offer the first complete Sample to Insight solution for analysis of hereditary diseases. Our solution, anchored by the GeneReader NGS System, provides the complete solution that labs need to efficiently and reliably perform genetic analysis.”